94 related articles for article (PubMed ID: 25976781)
1. Calponin-h2 is upregulated in the tissues and plasma of patients with breast cancer.
Ji T; Ma F; Huo L; Guo X; Chen B; Zhou Q
Mol Med Rep; 2015 Aug; 12(2):2886-92. PubMed ID: 25976781
[TBL] [Abstract][Full Text] [Related]
2. Calponin-h2: a potential serum marker for the early detection of human breast cancer?
Debald M; Jin JP; Linke A; Walgenbach KJ; Rauch P; Zellmer A; Fimmers R; Kuhn W; Hartmann G; Walgenbach-Brünagel G
Tumour Biol; 2014 Nov; 35(11):11121-7. PubMed ID: 25099617
[TBL] [Abstract][Full Text] [Related]
3. The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
Ławicki S; Szmitkowski M; Wojtukiewicz M
Clin Chim Acta; 2006 Sep; 371(1-2):112-6. PubMed ID: 16631152
[TBL] [Abstract][Full Text] [Related]
4. [Long non-coding RNA HOTAIR in plasma as a potential biomarker for breast cancer diagnosis].
Zhang KJ; Zhang Y; Luo ZL; Liu L; Yang J; Wu LC; Yu SS; Liu JB
Nan Fang Yi Ke Da Xue Xue Bao; 2016 Apr; 36(4):488-92. PubMed ID: 27113175
[TBL] [Abstract][Full Text] [Related]
5. [Diagnostic value of combined detection of TPS, CA153 and CEA in breast cancer].
Zheng H; Luo RC
Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct; 25(10):1293-4, 1298. PubMed ID: 16234113
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
Samy N; Ragab HM; El Maksoud NA; Shaalan M
Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
[TBL] [Abstract][Full Text] [Related]
7. Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer.
Findeisen R; Albrecht S; Richter B; Deutschmann K; Zimmermann T; Distler W
Luminescence; 2000; 15(5):283-9. PubMed ID: 11038485
[TBL] [Abstract][Full Text] [Related]
8. Tenascin-W, a new marker of cancer stroma, is elevated in sera of colon and breast cancer patients.
Degen M; Brellier F; Schenk S; Driscoll R; Zaman K; Stupp R; Tornillo L; Terracciano L; Chiquet-Ehrismann R; Rüegg C; Seelentag W
Int J Cancer; 2008 Jun; 122(11):2454-61. PubMed ID: 18306355
[TBL] [Abstract][Full Text] [Related]
9. VEGF, M-CSF and CA 15-3 as a new tumor marker panel in breast malignancies: a multivariate analysis with ROC curve.
Ławicki S; Będkowska GE; Szmitkowski M
Growth Factors; 2013 Jun; 31(3):98-105. PubMed ID: 23688065
[TBL] [Abstract][Full Text] [Related]
10. Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients.
Toiyama Y; Miki C; Inoue Y; Okugawa Y; Tanaka K; Kusunoki M
Int J Cancer; 2009 Oct; 125(7):1657-62. PubMed ID: 19569242
[TBL] [Abstract][Full Text] [Related]
11. Detection of tumor markers including carcinoembryonic antigen, APC, and cyclin D2 in fine-needle aspiration fluid of breast.
Lee A; Kim Y; Han K; Kang CS; Jeon HM; Shim SI
Arch Pathol Lab Med; 2004 Nov; 128(11):1251-6. PubMed ID: 15508191
[TBL] [Abstract][Full Text] [Related]
12. N(1),N(12)-Diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers.
Hiramatsu K; Takahashi K; Yamaguchi T; Matsumoto H; Miyamoto H; Tanaka S; Tanaka C; Tamamori Y; Imajo M; Kawaguchi M; Toi M; Mori T; Kawakita M
Clin Cancer Res; 2005 Apr; 11(8):2986-90. PubMed ID: 15837752
[TBL] [Abstract][Full Text] [Related]
13. Statistical learning confirms the diagnostic significance of the anemia panel in breast cancer.
Biljan M; Dmitrović B; Kristek J; Šimundić AM; Mandić S; Šerić V; Margaretić D; Debeljak Ž
Clin Chem Lab Med; 2012; 50(9):1671-8. PubMed ID: 23104837
[TBL] [Abstract][Full Text] [Related]
14. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions.
Porcel JM; Vives M; Esquerda A; Salud A; Pérez B; Rodríguez-Panadero F
Chest; 2004 Dec; 126(6):1757-63. PubMed ID: 15596670
[TBL] [Abstract][Full Text] [Related]
15. Identification of specific nuclear structural protein alterations in human breast cancer.
Debald M; Franken S; Heukamp LC; Linke A; Wolfgarten M; Walgenbach KJ; Braun M; Rudlowski C; Gieselmann V; Kuhn W; Hartmann G; Walgenbach-Brünagel G
J Cell Biochem; 2011 Nov; 112(11):3176-84. PubMed ID: 21732413
[TBL] [Abstract][Full Text] [Related]
16. h2-Calponin is regulated by mechanical tension and modifies the function of actin cytoskeleton.
Hossain MM; Crish JF; Eckert RL; Lin JJ; Jin JP
J Biol Chem; 2005 Dec; 280(51):42442-53. PubMed ID: 16236705
[TBL] [Abstract][Full Text] [Related]
17. Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women.
Desmetz C; Bascoul-Mollevi C; Rochaix P; Lamy PJ; Kramar A; Rouanet P; Maudelonde T; Mangé A; Solassol J
Clin Cancer Res; 2009 Jul; 15(14):4733-41. PubMed ID: 19584157
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of human leukocyte antigen-G expression and its clinical significance in ductal breast cancer.
Chen HX; Lin A; Shen CJ; Zhen R; Chen BG; Zhang X; Cao FL; Zhang JG; Yan WH
Hum Immunol; 2010 Sep; 71(9):892-8. PubMed ID: 20547193
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of serum KL-6, a mucin-like glycoprotein, as a tumor marker for breast cancer.
Ogawa Y; Ishikawa T; Ikeda K; Nakata B; Sawada T; Ogisawa K; Kato Y; Hirakawa K
Clin Cancer Res; 2000 Oct; 6(10):4069-72. PubMed ID: 11051258
[TBL] [Abstract][Full Text] [Related]
20. Use of p63 and CD10 in the differential diagnosis of papillary neoplasms of the breast.
de Moraes Schenka NG; Schenka AA; de Souza Queiroz L; de Almeida Matsura M; Vassallo J; Alvarenga M
Breast J; 2008; 14(1):68-75. PubMed ID: 18086274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
